donepezil has been researched along with Stroke in 23 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia." | 9.12 | A randomized, placebo-controlled study of donepezil in poststroke aphasia. ( Berthier, ML; Fernández, I; Green, C; Higueras, C; Hinojosa, J; Martín, MC, 2006) |
| "Donepezil, a primarily central acetylcholinesterase inhibitor, could potentiate learning in subjects with stroke by amplifying cholinergic input to the cerebral cortex from the nucleus basalis of Meynert." | 9.11 | Donepezil as an adjuvant to constraint-induced therapy for upper-limb dysfunction after stroke: an exploratory randomized clinical trial. ( Behrman, AL; Davis, SE; Gonzalez Rothi, LJ; Helms, KM; Nadeau, SE; Reid, K; Stidham, BS; Wu, SS, 2004) |
| "This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD)." | 7.96 | Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option. ( Han, W; Li, H; Yang, H, 2020) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 7.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "Donepezil has been proven effective in the treatment of Alzheimer's disease and vascular dementia." | 6.76 | Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study. ( Chang, WH; Kim, YH; Lee, PK; Ohn, SH; Park, CH; Park, YH, 2011) |
| "We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia." | 5.12 | A randomized, placebo-controlled study of donepezil in poststroke aphasia. ( Berthier, ML; Fernández, I; Green, C; Higueras, C; Hinojosa, J; Martín, MC, 2006) |
| "Donepezil, a primarily central acetylcholinesterase inhibitor, could potentiate learning in subjects with stroke by amplifying cholinergic input to the cerebral cortex from the nucleus basalis of Meynert." | 5.11 | Donepezil as an adjuvant to constraint-induced therapy for upper-limb dysfunction after stroke: an exploratory randomized clinical trial. ( Behrman, AL; Davis, SE; Gonzalez Rothi, LJ; Helms, KM; Nadeau, SE; Reid, K; Stidham, BS; Wu, SS, 2004) |
| "0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche en l'Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks." | 5.10 | Donepezil in vascular dementia: a randomized, placebo-controlled study. ( Doody, R; Helme, R; Kertesz, A; Mintzer, J; Pratt, RD; Taubman, K; Wilkinson, D, 2003) |
| "Small studies performed in chronic stroke patients have indicated that single doses of reboxetine or citalopram improved different aspects of motor functions and that long-lasting application of donepezil reduced aphasic symptoms." | 4.84 | Pharmacotherapy in restorative neurology. ( Liepert, J, 2008) |
| "Pharmacotherapy of aphasia had been discussed for the last twenty years with first bromocriptine and amphetamine and then serotoninergic, GABAergic and cholinergic agents." | 4.84 | Pharmacotherapy of aphasia: myth or reality? ( de Boissezon, X; de Boysson, C; Démonet, JF; Peran, P, 2007) |
| "Donepezil, a selective acetylcholinesterase (AchE) inhibitor, enhances stroke-induced neurogenesis within subventricular zone (SVZ)." | 3.96 | Donepezil promotes neurogenesis via Src signaling pathway in a rat model of chronic cerebral hypoperfusion. ( Cui, K; Fu, X; Gao, Y; Li, N; Lu, Z; Man, J; Wang, J; Yu, L; Zhang, D, 2020) |
| "This pilot study designed to evaluate the efficacy and safety of MAO-B inhibitor in comparison with Donepezil (DNP) in elderly Chinese patients with Alzheimer disease (AD)." | 3.96 | Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option. ( Han, W; Li, H; Yang, H, 2020) |
| "Sixteen patients with Alzheimer's disease (AD) and 15 patients with vascular dementia (VaD) associated with subcortical white matter lesions or subcortical cardiovascular accidents (CVAs) were treated with donepezil for 16 weeks." | 3.73 | Treating dementia patients with vascular lesions with donepezil: a preliminary analysis. ( Ledakis, GE; Libon, DJ; Thomas, DA, 2005) |
| "The network meta-analysis was used to evaluate the efficacy of acupuncture combined with other therapies in the treatment of post stroke cognitive impairment (PSCI)." | 3.01 | The efficacy of acupuncture combined with other therapies in post stroke cognitive impairment: A network meta-analysis. ( Dong, X; Huo, H; Li, S; Liu, Y; Wang, D; Wang, Y; Zhang, H; Zhang, Y; Zhao, D, 2023) |
| "Donepezil has been proven effective in the treatment of Alzheimer's disease and vascular dementia." | 2.76 | Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study. ( Chang, WH; Kim, YH; Lee, PK; Ohn, SH; Park, CH; Park, YH, 2011) |
| "Donepezil-treated participants experienced a 14-point greater improvement in the FIM-motor score compared to either galantamine-treated participants or the historical comparator group (repeated measures mixed model, group x time interaction p < 0." | 2.73 | An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients. ( Butters, M; Cabacungan, L; Dew, MA; Koenig, K; Lenze, EJ; Mulsant, BH; Munin, MC; Penrod, L; Pollock, BG; Reynolds, CF; Skidmore, E; Whyte, EM, 2008) |
| "Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression." | 2.58 | The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia. ( Du, G; Fu, Q; Huang, L; Shu, B; Zhang, D; Zhang, X, 2018) |
| "Donepezil was shown to provide benefits in cognition, global function, and activities of daily living compared with placebo." | 2.43 | Use of antidementia agents in vascular dementia: beyond Alzheimer disease. ( Farlow, MR, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Washida, K | 1 |
| Kitajima, E | 1 |
| Tanaka, T | 1 |
| Ikeda, S | 1 |
| Chiba, T | 1 |
| Noda, K | 1 |
| Yoshimoto, T | 1 |
| Fukuma, K | 1 |
| Saito, S | 1 |
| Ihara, M | 1 |
| Li, S | 1 |
| Wang, D | 1 |
| Zhang, Y | 1 |
| Huo, H | 1 |
| Liu, Y | 1 |
| Wang, Y | 1 |
| Zhao, D | 1 |
| Dong, X | 1 |
| Zhang, H | 1 |
| Man, J | 1 |
| Cui, K | 1 |
| Fu, X | 1 |
| Zhang, D | 2 |
| Lu, Z | 1 |
| Gao, Y | 1 |
| Yu, L | 1 |
| Li, N | 1 |
| Wang, J | 1 |
| Yang, H | 1 |
| Han, W | 1 |
| Li, H | 1 |
| Zhang, X | 1 |
| Shu, B | 1 |
| Huang, L | 1 |
| Fu, Q | 1 |
| Du, G | 1 |
| Cramer, SC | 1 |
| Whyte, EM | 1 |
| Lenze, EJ | 1 |
| Butters, M | 1 |
| Skidmore, E | 1 |
| Koenig, K | 1 |
| Dew, MA | 1 |
| Penrod, L | 1 |
| Mulsant, BH | 1 |
| Pollock, BG | 1 |
| Cabacungan, L | 1 |
| Reynolds, CF | 1 |
| Munin, MC | 1 |
| Liepert, J | 1 |
| Chang, WH | 1 |
| Park, YH | 1 |
| Ohn, SH | 1 |
| Park, CH | 1 |
| Lee, PK | 1 |
| Kim, YH | 1 |
| Berthier, ML | 3 |
| Hinojosa, J | 3 |
| Martín, Mdel C | 1 |
| Fernández, I | 2 |
| Rabadi, MH | 1 |
| Blass, J | 1 |
| Wilkinson, D | 1 |
| Doody, R | 1 |
| Helme, R | 1 |
| Taubman, K | 1 |
| Mintzer, J | 1 |
| Kertesz, A | 1 |
| Pratt, RD | 1 |
| Pujol, J | 1 |
| Gironell, A | 1 |
| Kulisevsky, J | 1 |
| Deus, J | 1 |
| Soriano-Mas, C | 1 |
| Erkinjuntti, T | 1 |
| Román, G | 1 |
| Gauthier, S | 1 |
| Feldman, H | 1 |
| Rockwood, K | 1 |
| Nadeau, SE | 1 |
| Behrman, AL | 1 |
| Davis, SE | 1 |
| Reid, K | 1 |
| Wu, SS | 1 |
| Stidham, BS | 1 |
| Helms, KM | 1 |
| Gonzalez Rothi, LJ | 1 |
| Thomas, DA | 1 |
| Libon, DJ | 1 |
| Ledakis, GE | 1 |
| Martínez-Vila, E | 1 |
| Murie-Fernández, M | 1 |
| Gállego Pérez-Larraya, J | 1 |
| Irimia, P | 1 |
| Hildebrandt, H | 1 |
| Bussmann-Mork, B | 1 |
| Schwendemann, G | 1 |
| de Boissezon, X | 1 |
| Peran, P | 1 |
| de Boysson, C | 1 |
| Démonet, JF | 1 |
| Farlow, MR | 1 |
| Green, C | 1 |
| Higueras, C | 1 |
| Martín, MC | 1 |
| McLay, RN | 1 |
| Ho, J | 1 |
| Ginestet, L | 1 |
| Ferrario, JE | 1 |
| Raisman-Vozari, R | 1 |
| Hirsch, EC | 1 |
| Debeir, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Donepezil to Promote Functional Recovery Post-stroke[NCT00868010] | Phase 3 | 200 participants (Anticipated) | Interventional | 2009-03-31 | Recruiting | ||
| Donepezil/ Galantamine in the Treatment of Post-stroke Cognitively Impaired Rehabilitating Elderly[NCT00227994] | Phase 4 | 40 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Effects of Combining Donepezil, Intensive Language Rehabilitation and Transcranial Direct Current Stimulation on Language Recovery and Brain Reorganization in Chronic Post-stroke Aphasia[NCT04134416] | Phase 3 | 20 participants (Actual) | Interventional | 2019-01-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants who withdrew due to side effects. (NCT00227994)
Timeframe: Measured throughout the study
| Intervention | participants (Number) |
|---|---|
| Galantamine | 5 |
| Donepezil | 5 |
Score on Functional Independence Measure (FIM) motor score, where 7 indicates total assistance/complete dependence and 91 is complete independence (NCT00227994)
Timeframe: Measured at weeks 0 and 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline FIM | Week 12 FIM | |
| Donepezil | 49.4 | 87.4 |
| Galantamine | 47.1 | 73.1 |
6 reviews available for donepezil and Stroke
| Article | Year |
|---|---|
The efficacy of acupuncture combined with other therapies in post stroke cognitive impairment: A network meta-analysis.
Topics: Acupuncture Therapy; Cognitive Dysfunction; Donepezil; Humans; Network Meta-Analysis; Stroke | 2023 |
The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia.
Topics: Aphasia; Databases, Factual; Donepezil; Humans; Memantine; Nootropic Agents; Stroke | 2018 |
Drugs to Enhance Motor Recovery After Stroke.
Topics: Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Humans; Indans; Levodopa; Motor Activity; Mot | 2015 |
Pharmacotherapy in restorative neurology.
Topics: Brain Injuries; Donepezil; Dopamine Uptake Inhibitors; Humans; Indans; Methylphenidate; Movement; No | 2008 |
Pharmacotherapy of aphasia: myth or reality?
Topics: Amphetamine; Aphasia; Bromocriptine; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; | 2007 |
Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Topics: Cholinesterase Inhibitors; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; | 2006 |
6 trials available for donepezil and Stroke
| Article | Year |
|---|---|
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.
Topics: Aged; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Donepezil; Feasibility S | 2008 |
Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study.
Topics: Adult; Aged; Brain Mapping; Cognition Disorders; Donepezil; Female; Functional Laterality; Humans; I | 2011 |
Donepezil in vascular dementia: a randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Double-Bli | 2003 |
Donepezil as an adjuvant to constraint-induced therapy for upper-limb dysfunction after stroke: an exploratory randomized clinical trial.
Topics: Arm; Cholinesterase Inhibitors; Combined Modality Therapy; Donepezil; Double-Blind Method; Female; H | 2004 |
Group therapy for memory impaired patients: a partial remediation is possible.
Topics: Aged; Analysis of Variance; Attention; Donepezil; Female; Humans; Indans; Intelligence Tests; Male; | 2006 |
A randomized, placebo-controlled study of donepezil in poststroke aphasia.
Topics: Acetylcholine; Adult; Aphasia; Brain; Cerebrovascular Circulation; Donepezil; Double-Blind Method; F | 2006 |
11 other studies available for donepezil and Stroke
| Article | Year |
|---|---|
A Nationwide Multi-Center Questionnaire Survey on the Real-World State and Clinical Management of Poststroke Dementia in Japan.
Topics: Aged; Cognitive Dysfunction; Cross-Sectional Studies; Dementia; Donepezil; Female; Galantamine; Huma | 2021 |
Donepezil promotes neurogenesis via Src signaling pathway in a rat model of chronic cerebral hypoperfusion.
Topics: Animals; Brain Ischemia; Cell Proliferation; Cerebral Ventricles; Donepezil; Doublecortin Protein; F | 2020 |
Efficacy and safety of MAO-B inhibitor versus donepezil in Chinese elderly stroke patients with Alzheimer disease: A potential therapeutic option.
Topics: Age Factors; Aged; Alzheimer Disease; China; Cholinesterase Inhibitors; Cognition; Donepezil; Female | 2020 |
Open-label study of donepezil in chronic poststroke aphasia.
Topics: Adult; Aged; Aphasia; Cholinesterase Inhibitors; Chronic Disease; Donepezil; Female; Humans; Indans; | 2003 |
Clinical trials in stroke in 2002.
Topics: Anticholesteremic Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia, Vascular; D | 2003 |
Beneficial effect of donepezil on sensorimotor function after stroke.
Topics: Cholinesterase Inhibitors; Donepezil; Female; Hemiplegia; Humans; Indans; Middle Aged; Piperidines; | 2003 |
Emerging therapies for vascular dementia and vascular cognitive impairment.
Topics: Carbamates; Cardiovascular Diseases; Cerebrovascular Disorders; Cholinesterase Inhibitors; Cognition | 2004 |
Treating dementia patients with vascular lesions with donepezil: a preliminary analysis.
Topics: Aged; Alzheimer Disease; Blood Vessels; Brain; Dementia; Dementia, Vascular; Donepezil; Female; Huma | 2005 |
Neuroprotection in vascular dementia.
Topics: Animals; Cholinesterase Inhibitors; Dementia, Vascular; Donepezil; Excitatory Amino Acid Antagonists | 2006 |
Posttraumatic stress disorder-like symptoms after treatment with acetylcholinesterase inhibitors.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Magnetic Res | 2007 |
Donepezil induces a cholinergic sprouting in basocortical degeneration.
Topics: Acetylcholine; Alzheimer Disease; Animals; Basal Nucleus of Meynert; Cerebral Cortex; Cholinergic Fi | 2007 |